Crosstalk between mismatch repair and base excision repair in human gastric cancer
Metrics: PDF 2318 views | HTML 3035 views | ?
Valeria Simonelli1,*, Giuseppe Leuzzi1,*, Giorgia Basile1,*, Mariarosaria D’Errico1, Paola Fortini1, Annapaola Franchitto1, Valentina Viti2, Ashley R. Brown3, Eleonora Parlanti1, Barbara Pascucci4, Domenico Palli5, Alessandro Giuliani1, Fabio Palombo6, Robert W. Sobol3,7,8, Eugenia Dogliotti1
1Department of Environment and Primary Prevention, Istituto Superiore di Sanità, Rome, Italy
2Istituto di Ricerche Biologia Molecolare P. Angeletti (IRBM), Pomezia (Rome), Italy
3University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA
4Institute of Cristallography, Consiglio Nazionale delle Ricerche, Monterotondo Stazione, Rome, Italy
5Molecular and Nutritional Epidemiology Unit, CSPO, Scientific Institute of Tuscany, Florence, Italy
6Takis Biotech, Castel Romano, Rome, Italy
7Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA
8Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA
*These authors have contributed equally to this work
Valeria Simonelli, email: [email protected]
Eugenia Dogliotti, email: [email protected]
Keywords: DNA repair, alkylation damage, gastric cancer, DNA polymerase β, mismatch repair
Received: September 02, 2015 Accepted: May 23, 2016 Published: June 20, 2016
DNA repair gene expression in a set of gastric cancers suggested an inverse association between the expression of the mismatch repair (MMR) gene MLH1 and that of the base excision repair (BER) gene DNA polymerase β (Polβ). To gain insight into possible crosstalk of these two repair pathways in cancer, we analysed human gastric adenocarcinoma AGS cells over-expressing Polβ or Polβ active site mutants, alone or in combination with MLH1 silencing. Next, we investigated the cellular response to the alkylating agent methyl methanesulfonate (MMS) and the purine analogue 6-thioguanine (6-TG), agents that induce lesions that are substrates for BER and/or MMR. AGS cells over-expressing Polβ were resistant to 6-TG to a similar extent as when MLH1 was inactivated while inhibition of O6-methylguanine-DNA methyltransferase (MGMT) was required to detect resistance to MMS. Upon either treatment, the association with MLH1 down-regulation further amplified the resistant phenotype. Moreover, AGS cells mutated in Polβ were hypersensitive to both 6-TG and MMS killing and their sensitivity was partially rescued by MLH1 silencing. We provide evidence that the critical lethal lesions in this new pathway are double strand breaks that are exacerbated when Polβ is defective and relieved when MLH1 is silenced. In conclusion, we provide evidence of crosstalk between MLH1 and Polβ that modulates the response to alkylation damage. These studies suggest that the Polβ/MLH1 status should be taken into consideration when designing chemotherapeutic approaches for gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.